News ESMO26: Sac-TMT delivers the goods in PD-L1-negative NSCLC Kelun and MSD's TROP2-directed ADC, sac-TMT, reduced the risk of disease progression or death by 51% when used first-line in PD-L1-negative NSCLC.
News Late-breakers to look out for at ASCO 2026 ASCO is just around the corner, and there is the usual fertile crop of high-profile trials to look out for among the late-breaker presentations.
News MSD's Sac-TMT delivers in first phase 3 readout MSD's TROP2-targeting antibody-drug conjugate sac-TMT, licensed from China's Kelun, has improved survival in a late-stage endometrial cancer trial.
News Kelun gets world-first approval for TROP2 ADC Kelun-Biotech has picked up another world-first approval for its TROP2-targeting ADC sac-TMT in non-small cell lung cancer.
News Kelun-Biotech first to bag TROP2 approval in lung cancer Kelun-Biotech wins first global regulatory approval - in China - for a TROP2-directed antibody-drug conjugate (ADC) in lung cancer.
News Kelun's MSD-partnered TROP2 drug gets first okay in China Kelun-Biotech has become the second drugmaker to bring a TROP2 ADC to regulatory approval, after its sac-TMT drug was cleared in China
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.